Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.

@article{Lacy2007LongtermRO,
  title={Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.},
  author={Martha Q. Lacy and Morie A Gertz and Angela Dispenzieri and Suzanne R. Hayman and Susan Michelle Geyer and Brian F. Kabat and Steven R. Zeldenrust and Shaji K Kumar and Philip R. Greipp and Rafael Fonseca and John A. Lust and Stephen Russell and Robert A Kyle and Thomas E Witzig and Peter Leif Bergsagel and Alexander Stewart and S Vincent Rajkumar},
  journal={Mayo Clinic proceedings},
  year={2007},
  volume={82 10},
  pages={1179-84}
}
OBJECTIVE To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma. PATIENTS AND METHODS From March 2004 through October 2004, 34 patients were registered for the study. They were treated with 25 mg/d of lenalidomide on days 1 through 21 of a 28-day cycle and 40 mg/d of dexamethasone on days 1 through 4, 9 through 12, and 17 through 20 of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 57 extracted citations

Lenalidomide: a new therapy for multiple myeloma.

Cancer treatment reviews • 2008
View 7 Excerpts
Highly Influenced

Multiple myeloma

Nature Reviews Disease Primers • 2017

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer

CL Bennett, C Angelotta, PR Yarnold
[letter]. JAMA • 2006

Multiple myeloma [ published correction appears in

RA Kyle, SV Rajkumar
N Engl J Med • 2005

Similar Papers

Loading similar papers…